Advertisement
HUTCHMED (China) Limited (HCM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
As of 02:40PM EDT. Market open.
| Previous Close | 20.85 |
| Open | 20.88 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 20.88 - 21.32 |
| 52 Week Range | 11.93 - 21.92 |
| Volume | |
| Avg. Volume | 114,645 |
| Market Cap | 3.628B |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.46 |
GlobeNewswireHUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces positive high-level results from the SAVANNAH Phase II trial that showed TAGRISSO® (osimertinib) p
GuruFocus.comHUTCHMED (China) Ltd (HCM) (Q2 2024) Earnings Call Highlights: Strong US Sales Propel Growth ...
HUTCHMED (China) Ltd (HCM) reports robust first-half profits and revenue growth, driven by US sales, while navigating regulatory and competitive challenges.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.